Market Cap (In USD)
1.94 Billion
Revenue (In USD)
186.37 Million
Net Income (In USD)
-163.41 Million
Avg. Volume
586.92 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 23.14-48.89
- PE
- -
- EPS
- -
- Beta Value
- 1.162
- ISIN
- US6047491013
- CUSIP
- 604749101
- CIK
- 1759425
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Christopher Peetz
- Employee Count
- -
- Website
- https://www.mirumpharma.com
- Ipo Date
- 2019-07-18
- Details
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
More Stocks
-
VRNO
-
KLRFM
-
GUJPETRGujarat Petrosynthese Limited
GUJPETR
-
PLSH
-
MTI
-
BXRDF
-
HUMXHuman Xtensions Ltd.
HUMX
-
SAGASaga Pure ASA
SAGA